HUGO Gene Nomenclature agreed to change CECR1 to the ADA2 gene and approved the name “Adenosine Deaminase 2”.  Pictured above is the ADA2 protein scientific ribbon model.

Due to the ongoing Covid-19 pandemic, we held a virtual conference for patients, which brought more than 100 patients and their family members together for a day-long summit on the latest with DADA2. You can watch the Conference Videos on our YouTube Channel: https://www.youtube.com/@dada2foundation/playlists .

Due to the Covid-19 pandemic, we held our 3rd International Conference in a virtual format.  More than 500 physicians and researchers from around the globe registered, and on any given day throughout the 3-day conference, more than 300 attended the conference from 30+ countries.  Watch the Conference Videos here: https://www.youtube.com/@dada2foundation/playlists

DADA2 Foundation initiates research and supported the development of the ADA2 Now Point of Care Testing Device, which can identify a DADA2 patient in as little as 30 minutes.

Published the world’s only and first Consensus Statement alongside 35 researchers & physicians and 3 patients in the Journal of the American Medical Association Network Open Access.

The DADA2 Foundation, Boston Children’s Hospital and MIT/Broad Institute study suggests that the carrier frequency of deleterious ADA2 variants is approximately 1 in 236 individuals, which translates into an estimated disease prevalence of 1 case per 222 000 individuals. This could suggest potentially 35,000 patients globally if fully diagnosed.

The DADA2 Foundation publishes  A History of the DADA2 Foundation.